3-(5-Methyl-3-trifluoromethyl-pyrazol-1-yl)-propylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(5-Methyl-3-trifluoromethyl-pyrazol-1-yl)-propylamine
• 英文别名: 3-[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]propan-1-amine
• 化学式: C₈H₁₂F₃N₃
• mdl: MFCD03419762
• 分子量: 207.2
• InChiKey: AKQDGIVPYKSDKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
  申请人：SANOFI

  公开号：EP2881390A1

  公开（公告）日：2015-06-10

  The present invention relates to compounds of the formula I, wherein R1, R2, R3, R4 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, cardiovascular diseases, inflammatory diseases or could show beneficial effects in pain, dyslipidemia, atherosclerosis wound healing and stroke. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R1、R2、R3、R4和X的含义如索赔中所示。式I的化合物是有价值的药理活性化合物。它们是高效且选择性可溶性环氧化酶抑制剂，例如，适用于肾衰竭、糖尿病肾病、2型糖尿病、心血管疾病、炎症性疾病的治疗和预防，或者在疼痛、血脂异常、动脉粥样硬化、伤口愈合和中风方面可能显示有益效果。此外，该发明涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。
• ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
  申请人：SANOFI

  公开号：EP2945950B1

  公开（公告）日：2017-03-01